Clinical Trials
25 trialsNivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
National Cancer Institute (NCI)
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
National Cancer Institute (NCI)
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
National Cancer Institute (NCI)
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
National Cancer Institute (NCI)
TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
National Cancer Institute (NCI)